Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBR759 Titration Study in Asian CKD Patients on Hemodialysis
NCT00704678Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2008
- Primary completion
- Jun 2010
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of SBR759 in hyperphosphatemia (4 arms), sponsored by Novartis. Primary endpoint: Responder rates achieving target serum phosphate levels at Week 12. Started Aug 2008; status: completed.
02
Drugs
SBR759
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT00704678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00704678.